Rechercher dans ce blog

Monday, January 31, 2022

Most COVID-19 vaccine clinics now taking walk-ins: Lambton public health - St. Thomas Times-Journal

Article content

The Sarnia-area health unit has opened the majority of its COVID-19 vaccine clinics to walk-ins amid the home stretch of the rollout, its top doctor says.

Advertisement

Article content

Appointments are still recommended to avoid lines but are not mandatory as Lambton public health’s clinics welcome all residents age five-plus looking for any of their three doses.

“We are in the home stretch,” Dr. Sudit Ranade said Monday in a statement. “We have many available appointments at the clinics in February and we’re urging those who have not been vaccinated to do so now.”

The London-area health unit made a similar announcement Monday.

Ranade previously said demand is expected to wane as the calendar flips to February.

“So (Lambton public health) will continue to offer clinics this month but are basing future schedules on demand,” he said in the statement.

The health unit added it’s “happy” to report the provincial supply of the Pfizer vaccine has stabilized, so that brand will now be available to residents age 30 and older. Sarnia-Lambton residents younger than 30 were already receiving Pfizer for their first, second or third doses.

“Vaccination continues to be the most important method of keeping yourself and your loved ones safe,” Ranade said. “If you are eligible, please book an appointment or attend a clinic today. Your health and the welfare of our health-care system depends on it.”

Pop-up clinics are scheduled for Thursday at St. Patrick’s Catholic high school in Sarnia from 3 p.m. to 6:30 p.m. and Feb. 17 and Feb. 24 at the Florence and District and Brooke-Alvinston-Inwood community centres, respectively.

Advertisement

Article content

Visit GetTheVaccine.ca for more information.

The health unit also encouraged residents to contact local pharmacies or their family doctors for additional information on availability.

A total of 260,771 doses were administered to residents as of Monday via the health unit, doctors’ offices, family health teams, pharmacies and mobile clinics. Seventy-eight per cent of the five-plus population was fully immunized and 45 per cent had three doses.

The announcement came the same day restrictions eased across the province, including the reopening of indoor dining and recreational facilities with capacity limits.

Meanwhile, the deadliest month locally of the nearly two-year pandemic has come to an end. The health unit reported the region’s 108th fatality this past weekend. Bluewater Health reported a man in his 50s died in hospital.

A total of 24 residents have died from the disease since Jan. 3.

Eighty-eight patients, including some people who lived elsewhere, have died in local hospital over the past two years.

The vaccination status of the deceased at home or in hospital has not been made available due to privacy concerns, officials have said.

Bluewater Health reported it was treating 35 COVID-positive patients Monday, with five in intensive care. Twenty-four were vaccinated and 11 were partially or unvaccinated.

The virus is causing longer waits in hospital as more people are being admitted than discharged most days, Bluewater Health officials said recently, but an outbreak inside the Sarnia hospital’s in-patient rehabilitation unit was declared over Monday.

Advertisement

Article content

“Diligent infection prevention and control measures were key in helping control this outbreak. Bluewater Health is grateful for the support of all staff and professional staff, patients and family, and the community during this time,” the two-site hospital group said in a statement.

The health unit was still overseeing 13 active outbreaks. They included long-term care and retirement homes, congregate and businesses.

Ranade has repeatedly cautioned daily COVID-19 case figures are a substantial underestimate due to the high transmissibility of the Omicron variant and recent changes to testing criteria.

tbridge@postmedia.com

@ObserverTerry

    Advertisement

    Comments

    Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

    Adblock test (Why?)


    Most COVID-19 vaccine clinics now taking walk-ins: Lambton public health - St. Thomas Times-Journal
    Read More

    Federal government invests in 15 projects that support the implementation of Canada's national dementia strategy - McGill Reporter - McGill Reporter

    A new initiative by McGill University’s Dementia Education Program is among the 15 projects that will receive funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities, announced the Honourable Jean-Yves Duclos today.

    The Dementia Community Investment (DCI) will invest $758,430 to support the development of Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning for Family/Friend Care Partners of People Living with Dementia. This project will adapt and enhance the existing bilingual Dementia Education Program workshop content to the current COVID-19 context by using a virtual learning platform to educate and support family/friend care partners of people living with dementia.

    The goal of TOTAL eLearning is to increase knowledge about dementia and decrease social isolation experienced by informal care partners. By creating a flexible and accessible virtual learning platform, this project will also enable rural populations to access resources and supports that have primarily been available only in urban settings.

    “Family and friend care partners of people living with dementia are often isolated, both physically and socially, and unfortunately, the pandemic has exacerbated these issues. We want to connect with this vulnerable population and provide a community education experience that is culturally relevant and engaging. The new TOTAL eLearning platform will allow us to deliver these needed resources in an online format to support the people who need it the most,” says the principal investigator for this initiative, Tamara Carver, PhD, Assistant Professor at the Institute of Health Sciences Education and Director of the Office of Education Technology and E-learning Collaboration for Health (Ed-TECH) at the McGill Faculty of Medicine and Health Sciences.

    TOTAL eLearning will reach diverse communities in Montreal as well as remote communities in rural Quebec. The future goal is to expand the reach nationally through partnerships with the Alzheimer Society of Canada, the Canadian Consortium on Neurodegeneration and Aging and Dementia Advocacy Canada.

    “This support from the Public Health Agency of Canada will allow us to further leverage the outstanding expertise within the Dementia Education Program and work with community partners to enhance the wellbeing of people living with dementia and their care partners,” says Vice-Principal (Health Affairs) and Dean of the Faculty of Medicine and Health Sciences at McGill University, David Eidelman, MDCM.  “By working together and finding innovative ways to connect with and support our communities, we will build healthier, more resilient societies.”

    Read the government press release

    Adblock test (Why?)


    Federal government invests in 15 projects that support the implementation of Canada's national dementia strategy - McGill Reporter - McGill Reporter
    Read More

    Moderna or Pfizer: Which vaccine is a better booster? Experts weigh in - CBC.ca

    Until there's some future vaccine designed specifically to target the highly transmissible Omicron variant, adults in Canada are encouraged to get their booster shot as soon as possible — which means either Pfizer or Moderna.

    Both mRNA vaccines offer significant protection against breakthrough infections and hospitalizations, but new research from data collected before Omicron hit shows Moderna's vaccine may offer slightly better protection compared to Pfizer.

    That may surprise people who had been turning Moderna down, said Kelly Grindrod, a pharmacist and associate professor at the University of Waterloo school of pharmacy.

    "They walk away from it because they think it's a lesser vaccine," she told Dr. Brian Goldman, host of CBC podcast The Dose. "But the evidence doesn't say Moderna is a lesser vaccine. Actually, it's quite the opposite." 

    A study published in the peer-reviewed Journal of the American Medical Association (JAMA) last week shows adults who received two doses of the Moderna vaccine had a lower risk of hospitalization compared to those who received two doses of the Pfizer-BioNTech vaccine. The research used data from March to August of last year when Delta was the dominant variant.

    As booster shots roll out across the country, Moderna may be a better choice for many over the age of 30 because of its slightly longer protection against infection, said Grindrod, the pharmacy vaccine lead for the Waterloo region.

    New research around which vaccine is best for specific populations — and Omicron — is evolving, but there are a few key things you need to know right now.

    How do the two vaccines compare?

    Doctors and public health officials have said that people should get whichever booster shot is readily available to them. 

    Both mRNA vaccines offer significant protection against COVID-19, Grindrod said, but studies comparing the two vaccines are showing Moderna has a slight edge. 

    "Now, if you're someone who's in your 40s and is otherwise healthy, is that going to be a huge difference for you? Probably not. It might be just a very small difference," she said.

    WATCH | Medical experts explain why the science behind boosters is sound:

    The safe science behind COVID-19 booster shots

    17 days ago
    Duration 1:55
    While some Canadians who have received their booster shots have later tested positive for COVID-19, medical experts agree that the science behind booster jabs is sound. 1:55

    But there is some research showing that for older populations or for those who have weaker immune systems, Moderna may offer slightly more protection against breakthrough infections, Grindrod said. 

    The researchers who published the study in JAMA found that although immune responses to Moderna and Pfizer's vaccines dropped six months after vaccination, antibody titers — a test used to detect the level of antibodies in blood — were higher with Moderna. 

    In another study published in the New England Journal of Medicine in December, researchers looked at the effectiveness of the two vaccines among health-care workers between December 2020 and May 2021.  

    It found that vaccine effectiveness after two doses were 88.8 per cent for Pfizer and 96.3 per cent for Moderna. 

    "Moderna does seem to have a more durable protection, which is going to protect you for potentially a bit longer against those breakthrough infections," Grindrod said.

    She added there are still a lot of questions about why Moderna is outperforming Pfizer. 

    She said it may be because the dosage is different between the vaccines. The regular full dose of Moderna is 100 micrograms of nucleoside-modified messenger RNA (mRNA) compared to Pfizer's full dose vaccine which is 30 micrograms.

    The Moderna booster shot is a half dose. The Pfizer-BioNTech booster is a full dose.

    "There's actually more mRNA in the half-dose Moderna than the full dose Pfizer. So when we're looking at protection, this slightly higher dose might actually give a slightly more durable immunity when it's a booster shot," Grindrod said. More data on booster shots is still needed, she said.

    Which mRNA vaccine better protects me from Omicron?

    New research is showing how well boosters are holding up in the Omicron wave — still protecting against infection, symptoms and hospitalization. 

    A new study shows that some adults who received two doses of the Moderna vaccine had a lower risk of hospitalization compared to those who received two doses of the Pfizer-BioNTech vaccine. (Lars Hagberg/The Canadian Press)

    But how long that protection lasts is still unknown, Grindrod said. 

    A report from the U.S. Centers for Disease Control and Prevention found that vaccine effectiveness against Omicron hospitalization fell to just 57 per cent in people who were more than six months out from a second shot, but grew to 90 per cent with a booster.

    A second CDC report looked at 25 U.S. states between April and December and similarly found that while defence against infection waned, those with boosters had much higher protection against symptoms both when Delta was dominant and when Omicron overtook it.

    And a third study from CDC researchers published in the the Journal of the American Medical Association found three shots of mRNA vaccines were close to 67 per cent effective against symptomatic disease from Omicron compared to the unvaccinated.

    It's not clear yet which booster is most effective against Omicron.

    Which vaccine should I get for my booster shot?

    Health Canada has authorized Moderna's COVID-19 vaccine (also known as Spikevax) and Pfizer-BioNTech's vaccine (Comirnaty) for booster-shot use in people 18 or older. 
    The dosage amounts differ between the two vaccines. The regular full dose of Moderna is 100 micrograms of nucleoside-modified messenger RNA (mRNA) compared to Pfizer’s full dose vaccine which is 30 micrograms. A Moderna booster is a half dose. (Jacques Corriveau/Radio-Canada)

    Whether or not you will be offered a COVID-19 booster shot is based on each province or territory's eligibility criteria and rollout plan.

    Which vaccine you get depends on your age and where you live. In some places, adults may be offered a choice.

    In Toronto, Durham and Waterloo regions, people aged 30 and up will only be offered Moderna.

    When it comes to 18 to 29-year-olds, Grindrod said Pfizer is generally the recommended vaccine.

    Nova Scotia is recommending people between 18 and 24 receive the Pfizer vaccine due to  "a rare, but increased risk of myocarditis/pericarditis in young adults from the Moderna vaccine as compared to the Pfizer vaccine."

    Last fall, the Ontario government offered a similar recommendation due to a "mild risk" of the rare heart condition myocarditis "out of an abundance of caution." 

    Heart inflammation after a COVID-19 infection can also happen, and doctors and other health experts have emphasized that the benefits of getting a COVID-19 vaccine outweigh the risk of heart inflammation.

    In this file photo from April 2021, a senior in Alberta gets a COVID-19 vaccination. Ontario pharmacist Kelly Grindrod suggests Moderna for anyone with a weakened immune system or who has more risk factors. (Alberta Health Services)

    Take what you can get, doctors say

    If you're 30-years-old or older and healthy, Grindrod said people should just take the first shot they can get. 

    And if you received the AstraZeneca or Johnson & Johnson shots for your first two doses, getting either the Moderna or Pfizer boosters that are available will still offer strong protection against COVID-19. 

    But if someone has a weakened immune system or has more risk factors, Grindrod leans towards recommending Moderna for a booster shot.

    Dr. Iris Gorfinkel, a Toronto-based family doctor and vaccine researcher, emphasized that when it comes to reducing hospitalizations, both are "extremely effective."

    "It's not promising to be perfect, even when it comes to hospitalizations. We're going to see breakthrough infections with either vaccines, but those breakthrough infections are few and far between compared to populations who remain unvaccinated."

    Gorfinkel emphasizes that the differences between Pfizer and Moderna's vaccines "are small."

    "The truth is they both really work well."

    Both Pfizer and Moderna have launched studies of Omicron-specific boosters.

    Gorfinkel said it will  take real-world study data comparing the vaccines head-to-head against Omicron to really tell if one offers better protection.


    Written and produced by Stephanie Dubois, with files from Adam Miller and Amina Zafar.

    Adblock test (Why?)


    Moderna or Pfizer: Which vaccine is a better booster? Experts weigh in - CBC.ca
    Read More

    'Is this permanent?' long-haul COVID sufferers lack answers - CP24 Toronto's Breaking News


    Laura Ungar And Lindsey Tanner, The Associated Press
    Published Monday, January 31, 2022 6:31AM EST
    Last Updated Monday, January 31, 2022 6:31AM EST

    More than a year after a bout with COVID-19, Rebekah Hogan still suffers from severe brain fog, pain and fatigue that leave her unable to do her nursing job or handle household activities.

    Long COVID has her questioning her worth as a wife and mother.

    “Is this permanent? Is this the new norm?” said the 41-year-old Latham, New York, woman, whose three children and husband also have signs of the condition. “I want my life back.”

    More than a third of COVID-19 survivors by some estimates will develop such lingering problems. Now, with omicron sweeping across the globe, scientists are racing to pinpoint the cause of the bedeviling condition and find treatments before a potential explosion in long COVID cases.

    Could it be an autoimmune disorder? That could help explain why long COVID-19 disproportionately affects women, who are more likely than men to develop autoimmune diseases. Could microclots be the cause of symptoms ranging from memory lapses to discolored toes? That could make sense, since abnormal blood clotting can occur in COVID-19.

    As these theories and others are tested, there is fresh evidence that vaccination may reduce the chances of developing long COVID.

    It's too soon to know whether people infected with the highly contagious omicron variant will develop the mysterious constellation of symptoms, usually diagnosed many weeks after the initial illness. But some experts think a wave of long COVID is likely and say doctors need to be prepared for it.

    With $1 billion from Congress, the National Institutes of Health is funding a vast array of research on the condition. And clinics devoted to studying and treating it are popping up around the world, affiliated with places such as Stanford University in California and University College London.

    WHY DOES IT HAPPEN?

    Momentum is building around a few key theories.

    One is that the infection or remnants of the virus persist past the initial illness, triggering inflammation that leads to long COVID.

    Another is that latent viruses in the body, such as the Epstein-Barr virus that causes mononucleosis, are reactivated. A recent study in the journal Cell pointed to Epstein-Barr in the blood as one of four possible risk factors, which also include pre-existing Type 2 diabetes and the levels of coronavirus RNA and certain antibodies in the blood. Those findings must be confirmed with more research.

    A third theory is that autoimmune responses develop after acute COVID-19.

    In a normal immune response, viral infections activate antibodies that fight invading virus proteins. But sometimes in the aftermath, antibodies remain revved up and mistakenly attack normal cells. That phenomenon is thought to play a role in autoimmune diseases such as lupus and multiple sclerosis.

    Justyna Fert-Bober and Dr. Susan Cheng were among researchers at Cedars-Sinai Medical Center in Los Angeles who found that some people who have had COVID-19, including cases without symptoms, have a variety of these elevated “autoantibodies” up to six months after recovering. Some are the same ones found in people with autoimmune diseases.

    Another possibility is that tiny clots play a role in long COVID. Many COVID-19 patients develop elevated levels of inflammatory molecules that promote abnormal clotting. That can lead to blood clots throughout the body that can cause strokes, heart attacks and dangerous blockages in the legs and arms.

    In her lab at Stellenbosch University in South Africa, scientist Resia Pretorius has found microclots in blood samples from patients with COVID-19 and in those who later developed long COVID. She also found elevated levels of proteins in blood plasma that prevented the normal breakdown of these clots.

    She believes that these clotting abnormalities persist in many patients after an initial coronavirus infection and that they reduce oxygen distribution to cells and tissue throughout the body, leading to most if not all symptoms that have been linked to long COVID.

    IT CAN HIT NEARLY ANYONE

    While there's no firm list of symptoms that define the condition, the most common include fatigue, problems with memory and thinking, loss of taste and smell, shortness of breath, insomnia, anxiety and depression.

    Some of these symptoms may first appear during an initial infection but linger or recur a month or more later. Or new ones may develop, lasting for weeks, months or over a year.

    Because so many of the symptoms occur with other illnesses, some scientists question whether the coronavirus is always the trigger. Researchers hope their work will provide definitive answers.

    Long COVID affects adults of all ages as well as children. Research shows it is more prevalent among those who were hospitalized, but also strikes a significant portion who weren't.

    Retired flight attendant Jacki Graham's bout with COVID-19 at the beginning of the pandemic wasn't bad enough to put her in the hospital. But months later, she experienced breathlessness and a racing heart. She couldn't taste or smell. Her blood pressure shot up.

    In the fall of 2020, she became so fatigued that her morning yoga would send her back to bed.

    “I'm an early riser, so I'd get up and push myself, but then I was done for the day,” said Graham, 64, of Studio City, California. “Six months ago, I would have told you COVID has ruined my life.”

    Hogan, the New York nurse, also wasn't hospitalized with COVID-19 but has been debilitated since her diagnosis. Her husband, a disabled veteran, and children ages 9, 13 and 15 fell ill soon after and were sick with fever, stomach pains and weakness for about a month. Then all seemed to get a little better until new symptoms appeared.

    Hogan's doctors think autoimmune abnormalities and a pre-existing connective tissue disorder that causes joint pain may have made her prone to developing the condition.

    POTENTIAL ANSWERS

    There are no treatments specifically approved for long COVID, though some patients get relief from painkillers, drugs used for other conditions, and physical therapy. But more help may be on the horizon.

    Immunobiologist Akiko Iwasaki is studying the tantalizing possibility that COVID-19 vaccination might reduce long COVID symptoms. Her team at Yale University is collaborating with a patient group called Survivor Corps on a study that involves vaccinating previously unvaccinated long COVID patients as a possible treatment.

    Iwasaki, who is also an investigator with the Howard Hughes Medical Institute, which supports The Associated Press' Health and Science Department, said she is doing this study because patient groups have reported improvement in some people's long COVID symptoms after they got their shots.

    Study participant Nancy Rose, 67, of Port Jefferson, New York, said many of her symptoms waned after she got vaccinated, though she still has bouts of fatigue and memory loss.

    Two recently released studies, one from the U.S. and one from Israel, offer preliminary evidence that being vaccinated before getting COVID-19 could help prevent the lingering illness or at least reduce its severity. Both were done before omicron emerged.

    Neither has been published in a peer-reviewed journal, but outside experts say the results are encouraging.

    In the Israeli study, about two-thirds of participants received one or two Pfizer shots; the others were unvaccinated. Those who had received two shots were at least half as likely to report fatigue, headache, muscle weakness or pain and other common long COVID symptoms as the unvaccinated group.

    UNCERTAIN FUTURE

    With few clear answers yet, the future is murky for patients.

    Many, like Graham, see improvement over time. She sought help through a long COVID program at Cedars-Sinai, enrolled in a study there in April 2021, and was vaccinated and boosted.

    Today, she said, her blood pressure is normal, and her sense of smell and energy level are getting closer to pre-COVID levels. Still, she wound up retiring early because of her ordeal.

    Hogan still struggles with symptoms that include agonizing nerve pain and “spaghetti legs,” or limbs that suddenly become limp and unable to bear weight, a condition that also affects her 13-year-old son.

    Some scientists worry that long COVID in certain patients might become a form of chronic fatigue syndrome, a poorly understood, long-lasting condition that has no cure or approved treatment.

    One thing's for sure, some experts say: Long COVID will have a huge effect on individuals, health care systems and economies around the world, costing many billions of dollars.

    Even with insurance, patients can be out thousands of dollars at a time when they're too sick to work. Graham, for example, said she paid about $6,000 out of pocket for things like scans, labs, doctor visits and chiropractic care.

    Pretorius, the scientist in South Africa, said there is real worry things could get worse.

    “So many people are losing their livelihoods, their homes. They can't work anymore,” she said. “Long COVID will probably have a more severe impact on our economy than acute COVID.”

    Adblock test (Why?)


    'Is this permanent?' long-haul COVID sufferers lack answers - CP24 Toronto's Breaking News
    Read More

    Sunday, January 30, 2022

    Coronavirus NYC: City to offer free, at-home delivery of antiviral pills - WABC-TV

    NEW YORK (WABC) -- On Sunday, Mayor Eric Adams was back to focusing on the pandemic, which in the last couple of weeks, cases were improving significantly.

    Adams says it helps that 75 percent of New Yorkers are now vaccinated, and access to testing is now better than ever. People can get vaccinated at home, test at home - and now, if they are COVID positive, as long as they have a prescribing doctor in the city, they can get medication delivered at home.


    "The city will also offer at-home delivery of COVID antiviral pills and to eligible New Yorkers who need them, and we're going to do it with the magic New York word - we're going to do it for free. For free," Adams said, "delivering the anti-viral pills to you at home if you're an eligible New Yorker and is for free."

    The city is already providing vaccines for free at home for those who request them. Delivery of the medications will work the same way -- so that no one who is sick has to go out and risk exposing others to get treatment.

    "Oral antiviral pills...for five days helps stop the virus from reproducing, which reduces the amount of virus in the body, and prevents symptoms from getting worse," said NYC Health Commissioner Dr. Dave Chokshi.

    Questions remain about how much longer we can declare victory over the omicron surge, and whether it will change mandates. There are no indications of any changes yet, in fact, Mayor Adams thanked his predecessor for putting the existing mandates in place.

    national geographic covid newsletter sign up

    MORE CORONAVIRUS COVID-19 COVERAGE


    Omicron variant symptoms: what to know even if you are vaccinated
    New York City COVID-19 Vaccine Tracker
    New Jersey COVID-19 Vaccine Tracker
    Centers for Disease Control and Prevention on coronavirus
    Submit a News Tip or Question

    ----------
    * Get Eyewitness News Delivered
    * More New York City news
    * Send us a news tip
    * Download the abc7NY app for breaking news alerts
    * Follow us on YouTube

    Submit a News Tip

    Copyright © 2022 WABC-TV. All Rights Reserved.

    Adblock test (Why?)


    Coronavirus NYC: City to offer free, at-home delivery of antiviral pills - WABC-TV
    Read More

    Gottlieb predicts kids under 5 could get COVID vaccine by early March - New York Post

    Former FDA Commissioner Dr. Scott Gottlieb said Sunday that a COVID-19 vaccine for children age 4 and under could be approved by early March.

    Gottlieb said the authorization would depend on whether federal officials move forward with Pfizer’s two-dose candidate, as opposed to the three-dose one added last month to the company’s clinical trials.

    The two-dose shot could presumably be approved the fastest of the two, since trials on it are further ahead, so it’s just a question of whether its potency is considered enough protection for the age group at this point, Gottlieb said.

    “Getting two doses into a child can provide baseline immunity that protects them from severe disease [and] from hospitalization,” the-ex-Food and Drug Administration chief told anchor Margaret Brennan on CBS’s “Face the Nation.”

    “And I think that may be why federal health officials are rethinking this if, in fact, they decide to authorize this on the basis of two doses. It could be out much sooner, perhaps as early as early March.”

    Vaccine vial.
    Pfizer found that two shots didn’t elicit the same kind of robust immune response in 2- to 5-year-olds as with adults.
    Ute Grabowsky/Photothek via Getty Images

    Pfizer had announced that it was amending its clinical trials and reviewing the effects of a third dose after finding two shots didn’t elicit the same kind of robust immune response in 2- to 5-year-olds as with adults.

    But Gottlieb said it may be enough that the two-dose regimen prevents severe disease, as opposed to stopping infection entirely.

    “I think the decision matrix has changed around the vaccine for [ages] 6 months to 4 years old and so far as we know that the vaccine isn’t as protective at preventing infection,” he said.

    Child gets vaccinated.
    Authorization would depend on whether federal officials move forward with Pfizer’s two-dose candidate, as opposed to the three-dose one added last month.
    Ute Grabowsky/Photothek via Getty Images

    “Previously, we had data showing that the childhood vaccine for 6 months to 4 years wasn’t as protective against infection as the adult vaccine,” he said.

    “That’s the reason why they pushed it out and asked for that third dose. But now, if the goal of the vaccine is to get baseline immunity in the kids to prevent really bad outcomes, and you’re really not using the vaccine as a tool to prevent infection in the first place, two doses could do that,” he continued.

    Last week, Dr. Anthony Fauci offered a different prediction.

    Child gets vaccinated.
    The two-dose Pfizer vaccine has been authorized for kids 5 and older since late October.
    Joseph Prezioso/AFP via Getty Images

    “It looks like it will be a three-dose regimen,” he said at a White House COVID-19 briefing on Wednesday, though he added that he can’t speak for the FDA, which must give the first round of potential approval before use, followed by the CDC for the final OK.

    The two-dose Pfizer vaccine has been authorized for kids 5 and older since late October, while anyone 12 and up are eligible for an additional booster.

    Adblock test (Why?)


    Gottlieb predicts kids under 5 could get COVID vaccine by early March - New York Post
    Read More

    Scientists on alert over rising cases caused by Omicron cousin BA.2 - Toronto Sun

    Article content

    CHICAGO — The highly transmissible Omicron variant of the SARS-CoV-2 virus – the most common form of which is known as BA.1 – now accounts for nearly all of the coronavirus infections globally, although dramatic surges in COVID cases have already peaked in some countries.

    Advertisement

    Article content

    Scientists are now tracking a rise in cases caused by a close cousin known as BA.2, which is starting to outcompete BA.1 in parts of Europe and Asia. The following is what we know so far about the new subvariant:

    “STEALTH” SUBVARIANT

    Globally, BA.1 accounted for 98.8% of sequenced cases submitted to the public virus tracking database GISAID as of Jan. 25. But several countries are reporting recent increases in the subvariant known as BA.2, according to the World Health Organization.

    In addition to BA.1 and BA.2, the WHO lists two other subvariants under the Omicron umbrella: BA.1.1.529 and BA.3. All are closely related genetically, but each features mutations that could alter how they behave.

    Trevor Bedford, a computational virologist at Fred Hutchinson Cancer Center who has been tracking the evolution of SARS-CoV-2, wrote on Twitter on Friday that BA.2 represents roughly 82% of cases in Denmark, 9% in the UK and 8% in the United States, based on his analysis of sequencing data from the GISAID database and case counts from the Our World in Data project at the University of Oxford.

    Advertisement

    Article content

    The BA.1 version of Omicron has been somewhat easier to track than prior variants. That is because BA.1 is missing one of three target genes used in a common PCR test. Cases showing this pattern were assumed by default to be caused by BA.1.

    BA.2, sometimes known as a “stealth” subvariant, does not have the same missing target gene. Instead, scientists are monitoring it the same way they have prior variants, including Delta, by tracking the number of virus genomes submitted to public databases such as GISAID.

    As with other variants, an infection with BA.2 can be detected by coronavirus home tests kits, though they cannot indicate which variant is responsible, experts said.

    MORE TRANSMISSIBLE?

    Some early reports indicate that BA.2 may be even more infectious than the already extremely contagious BA.1, but there is no evidence so far that it is more likely to evade vaccine protection.

    Advertisement

    Article content

    Danish health officials estimate that BA.2 may be 1.5 times more transmissible than BA.1, based on preliminary data, though it likely does not cause more severe disease.

    We apologize, but this video has failed to load.

    In England, a preliminary analysis of contact tracing from Dec. 27, 2021, through Jan. 11, 2022, by the U.K. Health Security Agency (HSA) suggests that household transmission is higher among contacts of people infected with BA.2 (13.4%) compared with other Omicron cases (10.3%).

    The HSA found no evidence of a difference in vaccine effectiveness, according to the Jan. 28 report.

    A critical question is whether people who were infected in the BA.1 wave will be protected from BA.2, said Dr. Egon Ozer, an infectious disease expert at Northwestern University Feinberg School of Medicine in Chicago.

    That has been a concern in Denmark, where some places that saw high case counts of BA.1 infections were reporting rising cases of BA.2, Ozer said.

    If prior BA.1 infection does not protect against BA.2, “this could be sort of a two-humped camel kind of wave,” Ozer said. “It’s too early to know if that will happen.”

    The good news, he said, is that vaccines and boosters still “keep people out of the hospital and keep people from dying.”

      Advertisement

      Comments

      Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

      Adblock test (Why?)


      Scientists on alert over rising cases caused by Omicron cousin BA.2 - Toronto Sun
      Read More

      The Detail: Boosting our chances against a Covid-19 outbreak - Stuff.co.nz

      The Detail is a daily news podcast produced for RNZ by Newsroom and is published on Stuff with permission. Click on this link to subscribe to the podcast.

      OPINION: For weeks, if not months, New Zealanders have been told the arrival of Omicron in the community was a matter of when, not if.

      And as it turned out, Sunday, January 23rd was the when.

      Aotearoa is now in the red traffic light setting. And the message – from government, opposition, and health officials alike – is clear: one of the key things people can do to help mitigate the worst effects of the Omicron variant is getting your booster shot.

      READ MORE:
      * Super Rugby: Kiwi teams poised to move to Queenstown bubble to keep season on track
      * Covid-19: More Waitangi events cancelled, this time at lower marae, due to Omicron
      * Covid-19: Will the vaccine protect me from Omicron?

      On today’s episode of The Detail, Emile Donovan speaks to immunologist Professor Graham Le Gros and vaccinologist Dr Helen Petousis-Harris about booster shots: What are they? What effect do they have? Is it really that important to get boosted? What does this tell us about the efficacy of the vaccine itself? And is this the new future – a new booster every few months, ad infinitum?

      For weeks, if not months, New Zealanders have been told the arrival of Omicron in the community was a matter of when, not if.

      Christel Yardley/Stuff

      For weeks, if not months, New Zealanders have been told the arrival of Omicron in the community was a matter of when, not if.

      The vaccine “is just prepping your immune system, getting all your immune cells involved”, says Le Gros, director of the Malaghan Institute of Medical Research.

      “You put the antigens in, they stimulate the immune system, they trickle along, everything gets activated – and then you starve the immune system.

      “Six months, even longer – it’s even better. Only the most potent immune cells for eliminating the virus you’re vaccinating against survive.

      “When you give the booster, the only immune cells left are your most elite immune forces – the ones with high-affinity neutralising antibody, the right T cells that see the right determinants. So when you boost, you only activate those.

      “They are killers. They will kill the virus very well. And that’s the immunological trick.”

      Le Gros says this explains the months-long period in between getting the second dose of the vaccine and the booster: It’s like basic training for the immune cells, and the longer they remain in the body, the better they’ll be.

      The ideal period is around six months – or even longer. But Omicron is here now, and because the original vaccine was designed for the first recorded variant of Covid-19, it isn’t that effective against Omicron – though undoubtedly it’s much better than nothing at all.

      Le Gros says this introduces a tension between having the most efficacious booster possible, and getting as much booster into people’s bodies as possible.

      “It’s better to get people boosted because at least you’ll get them immune, and they won’t have as many problems. Because it’s quite clear that it does protect you against Omicron – there’s enough of an effect that you get broad, cross-reactive immunity against Delta, Omicron, etc.”

      “Ideally we’d be boosted at six months … but unfortunately, it hasn’t waited … so we’ve got to get on with it and just compromise.”

      Adblock test (Why?)


      The Detail: Boosting our chances against a Covid-19 outbreak - Stuff.co.nz
      Read More

      Saturday, January 29, 2022

      Early warning of a COVID-19 surge on a university campus based on wastewater surveillance for SARS-CoV-2 at residence halls - DocWire News

      This article was originally published here

      Sci Total Environ. 2022 Jan 25:153291. doi: 10.1016/j.scitotenv.2022.153291. Online ahead of print.

      ABSTRACT

      As COVID-19 continues to spread globally, monitoring the disease at different scales is critical to support public health decision making. Surveillance for SARS-CoV-2 RNA in wastewater can supplement surveillance based on diagnostic testing. In this paper, we report the results of wastewater-based COVID-19 surveillance on Emory University campus that included routine sampling of sewage from a hospital building, an isolation/quarantine building, and 21 student residence halls between July 13th, 2020 and March 14th, 2021. We examined the sensitivity of wastewater surveillance for detecting COVID-19 cases at building level and the relation between Ct values from RT-qPCR results of wastewater samples and the number of COVID-19 patients residing in the building. Our results show that weekly wastewater surveillance using Moore swab samples was not sensitive enough (6 of 63 times) to reliably detect one or two sporadic cases in a residence building. The Ct values of the wastewater samples over time from the same sampling location reflected the temporal trend in the number of COVID-19 patients in the isolation/quarantine building and hospital (Pearson’s r < -0.8), but there is too much uncertainty to directly estimate the number of COVID-19 cases using Ct values. After students returned for the spring 2021 semester, SARS-CoV-2 RNA was detected in the wastewater samples from most of the student residence hall monitoring sites one to two weeks before COVID-19 cases surged on campus. This finding suggests that wastewater-based surveillance can be used to provide early warning of COVID-19 outbreaks at institutions.

      PMID:35090922 | DOI:10.1016/j.scitotenv.2022.153291

      Adblock test (Why?)


      Early warning of a COVID-19 surge on a university campus based on wastewater surveillance for SARS-CoV-2 at residence halls - DocWire News
      Read More

      Canada Omicron infections past peak, hospitalizations rising... - Thomson Reuters Foundation

      (Adds details from the briefing)

      Jan 28 (Reuters) - Canada has moved past the worst of the Omicron variant of coronavirus on some parameters, but Canadians still need to be prudent as hospitalizations were continuing to rise, the country's top health official said Friday.

      Omicron infections started spreading rapidly last month, taking over the dominant variant designation from Delta and forcing authorities to impose restrictions on businesses and social gatherings.

      Multiple indicators, including daily case counts and test positivity rates, now suggest that Omicron infections have peaked nationally in Canada, chief public health officer Theresa Tam told reporters at a briefing.

      "Getting to perhaps the peak is one thing but coming down the other side of the wave includes a lot of people could get infected, and some of them could potentially be infected with BA.2," Tam said, referring to a subvariant of the Omicron coronavirus variant that has been recorded in some European countries.

      Canada has detected over 100 cases of BA.2, which does not have the specific mutation seen with Omicron that can help to easily distinguish it from Delta, but the main Omicron variant was still behind the vast majority of COVID-19 infections.

      While the seven-day average case count dropped 28% as of Wednesday, compared with the week earlier, hospitalizations due to COVID continued to increase during the same period and over 1,200 patients were getting treated in intensive care units on average daily.

      "Presently lagging indicators are still rising ... this is why it continues to be important to limit spread as much as possible," Tam said. (Reporting by Ismail Shakil in Bengaluru and David Ljunggren in Ottawa; Editing by Bernard Orr)

      Our Standards: The Thomson Reuters Trust Principles.

      Adblock test (Why?)


      Canada Omicron infections past peak, hospitalizations rising... - Thomson Reuters Foundation
      Read More

      Canada Omicron infections past peak, hospitalizations rising: Health official - The Peninsula

      Ambulance crew members deliver a patient at Mount Sinai Hospital as officials warned of a "tsunami" of new coronavirus disease (COVID-19) cases in the days and weeks ahead due to the Omicron variant in Toronto, Ontario, Canada January 3, 2022. REUTERS/Cole Burston.

      Canada has moved past the worst of the Omicron variant of coronavirus on some parameters, but Canadians still need to be prudent as hospitalizations were continuing to rise, the country's top health official said Friday.

      Omicron infections started spreading rapidly last month, taking over the dominant variant designation from Delta and forcing authorities to impose restrictions on businesses and social gatherings.

      Multiple indicators, including daily case counts and test positivity rates, now suggest that Omicron infections have peaked nationally in Canada, chief public health officer Theresa Tam told reporters at a briefing.

      "Getting to perhaps the peak is one thing but coming down the other side of the wave includes a lot of people could get infected, and some of them could potentially be infected with BA.2," Tam said, referring to a subvariant of the Omicron coronavirus variant that has been recorded in some European countries.

      Canada has detected over 100 cases of BA.2, which does not have the specific mutation seen with Omicron that can help to easily distinguish it from Delta, but the main Omicron variant was still behind the vast majority of COVID-19 infections.

      While the seven-day average case count dropped 28% as of Wednesday, compared with the week earlier, hospitalizations due to COVID continued to increase during the same period and over 1,200 patients were getting treated in intensive care units on average daily.

      "Presently lagging indicators are still rising ... this is why it continues to be important to limit spread as much as possible," Tam said. 

      Adblock test (Why?)


      Canada Omicron infections past peak, hospitalizations rising: Health official - The Peninsula
      Read More

      Friday, January 28, 2022

      Early evidence that boosters seem to hold up against Omicron subvariant BA.2 - CBC News

      With BA.2 now spreading in more than 50 countries around the world, there's early hope that vaccine booster doses still hold up against the Omicron subvariant.

      An initial analysis of vaccine effectiveness by scientists in the U.K. — where the subvariant is expected to become dominant in the next month — found a similar level of protection against both siblings in the Omicron evolutionary family tree: BA.1, which is still dominant globally, and BA.2, which is rising in multiple countries.

      In the findings released on Thursday, which combined results from all COVID-19 vaccines being used in the U.K., the effectiveness in warding off symptomatic infection after two doses was nine per cent against BA.1 and 13 per cent against BA.2, after 25 or more weeks post-vaccination.

      The level of protection jumped to 63 per cent against BA.1 and 70 per cent against BA.2 two weeks following a booster shot, the analysis continued.

      That hopeful early finding comes as BA.2 cases are ticking up in Canada, with early federal data showing a slight rise in recent weeks.



      100+ BA.2 cases reported in Canada

      In a Public Health Agency of Canada briefing on Friday, Dr. Theresa Tam said the country's overall Omicron wave appears to be peaking.

      At the same time, more than 100 cases of BA.2 have been detected in Canada since November, with about 77 of those identifications coming from the National Microbiology Laboratory, plus further reporting from provinces and territories, she said.

      There's "always a possibility" that this wave could wind up extended, Tam said.

      South of the border, data also shows that BA.2 is being reported in 24 U.S. states, and in Denmark, it's displacing BA.1, all while the country is lifting its last restrictions.

      Danish scientists recently reported, reassuringly, that there's no difference in hospitalizations when compared with BA.1, and vaccines are expected to continue offering protection against severe illness — though early data does show that BA.2 may be more than 1.5 times more transmissible.

      That early signal echoes the properties of the original Omicron strain, which is highly contagious yet often leads to less severe disease than the Delta variant, in part thanks to global vaccination efforts.

      Even so, the variant is still putting significant pressure on many health-care systems due to the sheer number of cases, including in Canada, prompting the cancellation of scheduled surgeries in multiple provinces.

      WATCH | Canada's chief public health officer discusses BA.2 subvariant: 

      Tam discusses Omicron subvariant BA.2

      12 hours ago

      Duration 1:05

      Canada's chief public health officer, Dr. Theresa Tam, says Canada is one of the first countries to detect this variant, first reported in November of last year. 1:05

      'Increased growth rate' seen in U.K.

      The U.K. Health Security Agency (UKHSA) agreed on Friday that data shows BA.2 appears to have a substantial growth advantage over its predecessor.

      "We now know that BA.2 has an increased growth rate, which can be seen in all regions in England," said Dr. Susan Hopkins, chief medical advisor for the UKHSA, according to a Reuters report.

      Scientists in the U.K. now believe BA.2 will become the country's dominant strain in the next month, with the UKHSA's latest technical briefing showing a doubling time of roughly four days and a slightly higher transmission rate within households — which may result in either a new wave, or a plateau in current levels.

      Jason Kindrachuk, an assistant professor in medical microbiology and infectious diseases at the University of Manitoba in Winnipeg, said the world needs to watch the subvariant closely.

      It will be crucial to gauge why, exactly, BA.2 seems more contagious, he said, and whether it will increase total COVID-19 cases in Canada down the line or simply displace BA.1.

      "Is it something where BA.2 is going to move into those areas where we don't have a lot of immune coverage, even better than what the original Omicron is able to — but for the vast majority of the population it doesn't change things at all?" Kindrachuk questioned.

      Adblock test (Why?)


      Early evidence that boosters seem to hold up against Omicron subvariant BA.2 - CBC News
      Read More

      Early data indicate vaccines still protect against Omicron's sister variant - STAT

      New data show that vaccines still protect against a spinoff of the Omicron variant, a welcome sign as the world keeps a close eye on the latest coronavirus iteration.

      BA.2, as the sublineage is known, is part of the broader Omicron umbrella. Scientists are paying more attention to it as it begins to eat into the dominance of the more common Omicron strain, which is technically called BA.1.

      BA.1 is what has driven massive spikes in cases around the world, but in countries including India, the Philippines, South Africa, and several countries in Europe, BA.2 has been picking up proportional steam and demonstrating a growth advantage over BA.1. The two lineages share many mutations, but have their own individual genetic twists as well.

      As with any emerging variant, there are more questions than answers about BA.2’s transmissibility, severity, and ability to erode the immunity built by vaccination or prior infection. As the World Health Organization put it last week, “drivers of transmission and other properties of BA.2 are under investigation but remain unclear to date.”

      But data this week from the U.K. Health Security Agency — which has done some of the leading work on new variants — offered a piece of reassuring news: There does not seem to be any loss of vaccine effectiveness against BA.2 compared to BA.1.

      Vaccines already took a decent hit in the face of BA.1, particularly in their ability to prevent infection entirely, which is why so many immunized people have had breakthrough infections in recent weeks. But crucially, the vaccines’ protection against severe disease with Omicron has broadly stood up, and booster doses have helped shore up much of the protection that was lost.

      This week, the U.K. agency estimated that, for people at least two weeks out from their booster shot, vaccine effectiveness against symptomatic disease was 63% against BA.1, versus 70% for BA.2. While that might suggest that BA.2 is less of a threat to vaccine protection than its Omicron sister, the full estimate ranges overlapped.

      That helps answer one question about BA.2, but there remains another pressing one: what the spinoff’s snowballing means epidemiologically. The fact that it’s demonstrating a growth advantage in multiple countries suggests BA.2 might be able to outcompete BA.1 generally, though if that happens, it could be more of a slow ascendance than a lightning-quick grab of dominance. (When scientists in South Africa first identified what quickly became known as Omicron, they spelled out that there were already several lineages, including BA.2.)

      Jacob Lemieux, an infectious diseases physician at Massachusetts General Hospital who is helping lead a state program studying variants, said that in some countries, BA.2 is displacing BA.1, but that, “what we don’t know, and still have almost no information on, is what impact this will have on case counts, on hospitalizations, on death.”

      Variants can behave differently in different places, depending on the levels and types of immunity people have there and what else is spreading. Different variants can co-circulate. And the composition of infections can change — with an emerging strain coming to take the lead in a given place — even as the total number of cases declines or stays flat. Put another way, even if BA.2 becomes dominant, it doesn’t have to cause another spike.

      One factor that will help determine that is cross-protection: essentially, how well are the millions of people who’ve now been infected with BA.1 protected against infection from BA.2? Some variants offer better cross-protection against other forms of the virus than others. It appears that people who’ve been vaccinated and infected with Omicron have strong protection against Delta, for example.

      Another possibility is that BA.2 — if it is more transmissible in our current landscape than BA.1 — could cause another uptick in cases, but whatever spike occurs could be broadly limited to infections because of the high levels of population immunity. That is, the link between cases and subsequent hospitalizations and deaths could become even more decoupled than it already is.

      This week, for example, Danish authorities announced that they were ending most pandemic restrictions starting next week, because even with a high infection tally, there were few resulting hospitalizations.

      Adblock test (Why?)


      Early data indicate vaccines still protect against Omicron's sister variant - STAT
      Read More

      The Winnipeg Foundation Innovation Fund supports cutting-edge projects - UM Today

      February 1, 2024 —  Three interdisciplinary teams from the Rady Faculty of Health Sciences have received $100,000 grants from The Winnipeg...